Bio Solution Co.,Ltd.

A086820

KR7086820008

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
18,510 ^KRW	-6.84%		-5.46%	-4.54%

2023	Helixmith Co., Ltd announced that it has received KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd.	CI
2023	Helixmith Co., Ltd announced that it expects to receive KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd.	CI

Biosolution Co., Ltd. has filed an IPO.

April 11, 2018 at 12:00 am EDT

Biosolution Co., Ltd. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 24000 to KRW 29000 Transaction Features: Sponsor Backed Offering

Latest news about Bio Solution Co.,Ltd.

Helixmith Co., Ltd announced that it has received KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd.	Dec. 27	CI
Helixmith Co., Ltd announced that it expects to receive KRW 36.57534969 billion in funding from Bio Solution Co.,Ltd.	Dec. 19	CI
Bio Solution Co.,Ltd.(KOSDAQ:A086820) dropped from S&P Global BMI Index	23-09-18	CI
Biosolution Co.,Ltd. agreed to acquire 9.6% stake in Kyperion Co., Ltd. for KRW 4.5 billion.	21-09-08	CI
Bio Solution Co.,Ltd. announced that it has received KRW 42 billion in funding from Eum Private Equity, IBK Capital Corporation	21-08-12	CI
Bio Solution Co.,Ltd. announced that it has received KRW 60 billion in funding from Eum Private Equity, IBK Capital Corporation and other investors	21-08-12	CI
Bio Solution Co.,Ltd. announced that it expects to receive KRW 80 billion in funding from Eum Private Equity, IBK Capital Corporation	21-04-15	CI
Biosolution Co., Ltd.(KOSDAQ:A086820) added to S&P Global BMI Index	19-03-18	CI
Biosolution Co., Ltd. has completed an IPO in the amount of KRW 43.5 billion.	18-08-14	CI
Biosolution Co., Ltd. has filed an IPO.	18-04-11	CI
Biosolution Co., Ltd. has withdrawn its IPO.	18-04-10	CI
Biosolution Co., Ltd. has filed an IPO.	16-09-09	CI
MCTTBio Co.,Ltd. has withdrawn its IPO.	16-09-09	CI
Modern Cell & Tissue Technologies, Inc. announced that it has received KRW 4 billion in funding from Hyundai Venture Investment Corp. and Korea Investment Partners Co. Ltd.	14-10-14	CI
Modern Cell & Tissue Technologies, Inc. announced that it expects to receive KRW 4 billion in funding from Hyundai Venture Investment Corp. and Korea Investment Partners Co. Ltd.	14-09-29	CI

Bio Solution Co.,Ltd. is a Korea based company mainly engaged in the manufacturing and distribution of cell therapy products. The Company manufactures and sells cell based cosmetic raw materials and therapeutics with background in somatic and stem cell technology. The Companyâs major products include cosmetic raw material called stem water, which contains human stem cells has whitening and anti-wrinkling effects; as well as keratinocyte medication for severe burns and chondrocyte therapy product used to cure arthritis. The Company also researches and develops human tissue models for toxicity and efficacy testing using tissue engineering technology.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
BIO SOLUTION CO.,LTD.	-4.54%	108M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals